Skip to content

Nora D. Volkow

National Institute on Alcohol Abuse and Alcoholism

4 papers in the library · 237 citations · publishing 2016-2025

Papers

Structural and functional connectivity of the precuneus and thalamus to the default mode network

Human Brain Mapping October 14, 2016 Samantha Cunningham, Dardo Tomasi, Nora D. Volkow 221 citations

The precuneus and thalamus show strong structural and functional connections to each other and to the default mode network (DMN). Using diffusion tensor imaging and resting-state functional connectivity in 37 healthy adults, structural connectivity was greatest between the precuneus and thalamus, and connection fractional anisotropy increased with age. The precuneus also connected structurally to the hippocampus and middle prefrontal cortex but minimally to the angular gyrus and midcingulate cortex. Functionally, the precuneus connected most strongly with the angular gyrus.

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Journal of Psychopharmacology February 28, 2025 Dea Siggaard Stenbæk, Emil Deleuran Poulsen, Marie Katrine Klose Nielsen et al. 15 citations

A single 25 mg dose of psilocybin, a psychedelic compound, safely reduced alcohol consumption in ten adults with severe alcohol use disorder. Over 12 weeks, heavy drinking days fell by 37.5 percentage points and drinks per day dropped by 3.4. Participants also reported rapid and lasting decreases in craving and increases in self-efficacy. Peak blood levels of the drug varied widely among individuals, from 14 to 59 µg/L. The open-label, single-group design lacked a placebo control, so larger randomized trials are needed to confirm the findings.

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study

Research Square August 23, 2024 Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell et al. 1 citation

A single 25 mg dose of psilocybin, given with preparation and integration sessions, reduced alcohol consumption in ten adults with severe alcohol use disorder. Heavy drinking days dropped by 37.5 percentage points over 12 weeks, and drinks per day decreased by 3.4 units. Participants also reported rapid and lasting reductions in craving and increased self-efficacy. Blood levels of the active metabolite psilocin varied widely between individuals, peaking from 14 to 59 µg per liter. The open-label study, which lacked a placebo group, suggests that even a single psilocybin session may be safe and effective, but larger randomized controlled trials are needed.

No time to lose: the current state of research in rapid-acting psychotherapeutics

Neuropsychopharmacology January 1, 2024 Joshua A. Gordon, Nora D. Volkow, George F. Koob

Most treatments for psychiatric and substance use disorders require weeks to become effective, but some, like intravenous ketamine, can relieve symptoms within minutes to hours. Current research aims to discover new rapid-acting psychotherapeutics, including novel drug classes and innovative brain stimulation therapies, which are being studied in clinical and pre-clinical settings. Further investigation into the neurobiological mechanisms, effective therapeutic contexts, and implementation strategies is needed to fully realize the potential of these treatments.